Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 THIRD QUARTER AND NINE-MONTH

PRO-DEX, INC. ANNOUNCES FISCAL 2026 THIRD QUARTER

AND NINE-MONTH RESULTS

CA, April 30, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal

2026 third quarter ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal

year 2026 with the Securities and Exchange Commission today.

Quarter Ended March 31, 2026

sales for the three months ended March 31, 2026, increased $2.5 million, or 15%, to $19.9 million from $17.4 million for the three

months ended March 31, 2025, primarily due to an increase in shipments in the amount of $4.7 million

of our largest customer's next generation orthopedic handpiece offset by a decrease in repair revenue of $2.4 million similarly

generated from our largest customer. We also recognized $345,000 more NRE and prototype revenue during the three months ended March 31,

2026 as compared to the corresponding period of the prior fiscal year.

profit for the three months ended March 31, 2026, increased $335,000, or 6%, to $6.1 million from $5.8 million for the same period in

fiscal 2025. Gross margin decreased by 2 percentage points to 31% for the three months ended March 31, 2026, compared to 33% for the corresponding

period of the prior fiscal year. The decrease in gross margin is primarily due to an unfavorable product mix.

Operating expenses (which include

selling, general and administrative, and research and development expenses) for the quarter ended March 31, 2026, increased $881,000,

or 41%, to $3.0 million compared to $2.2 million in the prior fiscal year's corresponding quarter, reflecting increases in selling,

general and administrative expenses mostly due to higher expenses related to the acquisition of Advanced Precision Machining, LLC ("APM")

as well as increased personnel related expenses and includes approximately $200,000 in non-recurring legal and consulting fees related

to the APM acquisition offset by lower research and development expenditures.

Operating income for the quarter

ended March 31, 2026, decreased $546,000, or 15%, to $3.1 million compared to $3.6 million for the prior fiscal year's corresponding

quarter. The decrease is attributable to higher general and administrative expenses related to increased personnel costs, professional

fees incurred related to our APM acquisition (which are non-recurring), as well as the inclusion of APM's separate and continuing

general and administrative expenses.

Net income for the quarter ended

March 31, 2026, was $3.9 million or $1.20 per diluted share, compared to $3.3 million, or $0.98 per diluted share, for the corresponding

quarter in fiscal 2025. The net income for the quarter ended March 31, 2026, includes a realized gain in the amount of $2.3 million from

the payment of non-tradeable contingent value rights we hold in Monogram Technologies, Inc., related to its previous acquisition by Zimmer

Biomet Holdings, Inc.

Nine Months Ended March 31, 2026

sales for the nine months ended March 31, 2026, increased $8.0 million, or 16%, to $57.1

million from $49.1 million for the nine months

ended March 31, 2025, due primarily to an increase of $16.6 million in shipments of the next generation handpiece we sell to our largest

customer offset by a decrease of $5.2 million of their legacy handpiece and $5.5 million in decreased repair revenue from their legacy

handpiece. We also shipped $2.1 million more of our CMF drivers and batteries to various distributors during the nine months ended March

31, 2026, compared to the corresponding period of the prior fiscal year.

profit for the nine months ended March 31, 2026, increased $1.2 million, or 8%, compared

to the same period in fiscal 2025 due to increased sales. Our gross margin decreased by 3 percentage points to 30% for the nine months

ended March 31, 2026, compared to 33% for the corresponding period of the prior fiscal year, mostly as a result of a less favorable product

Operating expenses (which include

selling, general and administrative, and research and development expenses) for the nine months

ended March 31, 2026, increased $1.1 million, or 17%, to $7.8 million compared to $6.7 million in the prior fiscal year's

corresponding period. The increase is related to increased selling, general and administrative expenses mostly due to higher personnel-related

expenses offset by a decrease in research and development costs.

Operating income for nine

months ended March 31, 2026, increased $117,000, or 1%, to $9.5 million compared to $9.4 million for the corresponding period of

the prior fiscal year. The increase in operating income is attributable to higher sales and gross profit offset by the higher operating

expenses described above.

Net income for the nine

months ended March 31, 2026, was $10.8 million or $3.27 per diluted share, compared to net income of $7.8 million, or $2.31 per

diluted share, for the nine months ended March 31, 2025. Our net income for the nine months ended March 31, 2026, includes a $9.1 million

realized gain offset by the reversal of $3.2 million in unrealized gains related to our investment in Monogram Technologies, Inc. which

was acquired by Zimmer Biomet Holdings, Inc. during our second fiscal quarter.

"Our third quarter revenue

reflects a new quarterly record." said Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive

Officer. "Additionally, as we previously announced, we completed the acquisition of APM this quarter and remain excited about both

the additional revenue streams created as well as the expanded machining capacity and technology provided by this subsidiary." Mr.

Van Kirk continued, "I want to thank the Pro-Dex family for their efforts and execution. We are well positioned for sustained success

for the remainder of this fiscal year and beyond."

About Pro-Dex, Inc.:

specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers

and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting

software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Additionally, we provide

engineering, quality, and regulatory consulting services to our customers. Our APM subsidiary manufactures parts and assemblies for the

aerospace and defense industries in addition to providing several machined components to support Pro-Dex's customers. Pro-Dex, Inc.

also sells rotary air motors to a wide range of industries; however, these air motors comprise a de minimis portion of our business. Pro-Dex's

products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's websites at www.pro-dex.com

and www.advanced-precision.com.

concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities

laws. Statements regarding the Company's future events, developments, and future performance, as well as management's expectations, beliefs,

plans, estimates, or projections relating to the future, including, without limitation, statements concerning future growth are forward-looking

statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various

factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in

the Company's filings with the Securities and Exchange Commission.

PRO-DEX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

PRO-DEX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)